Back to top
more

PetMed Express (PETS)

(Delayed Data from NSDQ)

$3.20 USD

3.20
108,233

-0.04 (-1.23%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $3.18 -0.02 (-0.63%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 246)

Industry: Internet - Commerce

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

BioTelemetry Ties Up With Apple, Grows in Cardiac Monitoring

by Zacks Equity Research

BioTelemetry (BEAT) is consistently trying to improve its position in the cardiac monitoring and diagnostic services space.

    Zacks Equity Research

    Flexion's (FLXN) Zilretta Therapy to Fast Capture OA Market

    by Zacks Equity Research

    Flexion's (FLXN) commercial launch of Zilretta seems well-timed keeping in view how rapidly the osteoarthritis market is growing worldwide.

      Zacks Equity Research

      Veeva Systems (VEEV) Grows in Digital Asset Management Space

      by Zacks Equity Research

      Veeva Systems' (VEEV) constant endeavors seem to boost the Veeva Vault portfolio.

        Zacks Equity Research

        Amazon (AMZN) Witnesses Biggest Cyber Monday Bonanza Ever

        by Zacks Equity Research

        Cyber Monday becomes single biggest shopping day ever for Amazon.com Inc. (AMZN).

          Zacks Equity Research

          Here's Why You Should Invest in Baxter (BAX) Stock Right Now

          by Zacks Equity Research

          Baxter has witnessed favorable tidings on the regulatory front. The company enjoys strong presence in foreign markets.

            Zacks Equity Research

            Varian's Partners Penn Medicine, Proton Therapy in Focus

            by Zacks Equity Research

            Varian Medical's (VAR) solid prospects on the proton therapy space holds promise at the moment.

              Zacks Equity Research

              Genomic Health-Cleveland Diagnostics Deal to Boost Test Suite

              by Zacks Equity Research

              Genomic Health (GHDX) forges ahead with deals to strengthen hold in the high-potential prostate cancer therapeutics market.

                Zacks Equity Research

                GNC Holdings Grapples With Margin Weakness, Stiff Competition

                by Zacks Equity Research

                Weak margins, declining year-over-year revenues and rising operating costs continue to pose challenges to GNC Holdings (GNC).

                  Zacks Equity Research

                  Stryker Gains Ground on MAKO Robotic Unit Amid Forex Woes

                  by Zacks Equity Research

                  Solid performance by the MAKO robotic platform has been boosting Stryker's (SYK) revenues for long.

                    Zacks Equity Research

                    LabCorp's Covance Business Bounces Back on Chiltern Buyout

                    by Zacks Equity Research

                    Despite a dull show for several quarters, LabCorp's (LH) Covance Drug Development reported strong growth in the third quarter, courtesy of Chiltern acquisition. However, volume woes remain.

                      Zacks Equity Research

                      Align Technology (ALGN) Grows on InvisAlign System Strength

                      by Zacks Equity Research

                      Align Technology (ALGN) continues to gain from strength in the InvisAlign space.

                        Zacks Equity Research

                        Edwards Lifesciences' Pipeline Strong Amid Rising Expenses

                        by Zacks Equity Research

                        Edwards Lifesciences' (EW) aim at building its pipeline to fortify foothold across all operating businesses augurs well for the company. However, higher operating expenses are a concern.

                          Zacks Equity Research

                          Patterson Companies Dental Business Dull, Competition Rife

                          by Zacks Equity Research

                          Patterson's (PDCO) dental segment sales have been weak. The company faces stiff competition from at least 15 full-service distributors and small distributors.

                            Zacks Equity Research

                            Align Teams Up with Exocad to Expand in Digital Scanning

                            by Zacks Equity Research

                            Align's (ALGN) collaboration with CAD/CAM software provider, Exocad GmbH, is likely to integrate the Chairside CAD software into Align's iTero Element intraoral scanner.

                              Zacks Equity Research

                              Hologic (HOLX) Focuses on Breast Health, Ties Up with Clarius

                              by Zacks Equity Research

                              Hologic (HOLX) forges ahead with its efforts to strengthen hold in the high potential breast cancer screening market.

                                Zacks Equity Research

                                Hologic's FDA Nod for Quantra Software Boosts Breast Health

                                by Zacks Equity Research

                                Hologic (HOLX) is consistently trying to boost its Breast Health segment.

                                  Zacks Equity Research

                                  Alibaba (BABA) Announces Proposed Offering of Senior Notes (Revised)

                                  by Zacks Equity Research

                                  Alibaba Group Holding Limited (BABA) announces plans of offering senior unsecured notes. The move will help the company bring down its cost of capital, thereby strengthening its balance sheet.

                                    Zacks Equity Research

                                    The Zacks Analyst Blog Highlights: EVINE Live, ASOS, PetMed Express, Groupon, Amazon and Adobe Systems

                                    by Zacks Equity Research

                                    The Zacks Analyst Blog Highlights: EVINE Live, ASOS, PetMed Express, Groupon, Amazon and Adobe Systems

                                      Zacks Equity Research

                                      Add These 4 Promising Stocks to Your Cyber Monday Cart

                                      by Zacks Equity Research

                                      Cyber Monday is expected to be the largest online shopping fiesta of all times, courtesy upbeat job data and record low unemployment rate.

                                        Zacks Equity Research

                                        Here's Why You Should Add Amedisys (AMED) to Your Portfolio

                                        by Zacks Equity Research

                                        Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.

                                          Zacks Equity Research

                                          Here's Why You Should Invest in Masimo (MASI) Right Now

                                          by Zacks Equity Research

                                          Masimo (MASI) continues to grow on innovation and product launches.

                                            Zacks Equity Research

                                            Luminex (LMNX) at 52-Week High: What's Driving the Stock?

                                            by Zacks Equity Research

                                            Luminex (LMNX) gains from recent FDA approvals and product launches.

                                              Zacks Equity Research

                                              Zimmer Biomet Hurt by Supply Delay, Knee Challenges Remain

                                              by Zacks Equity Research

                                              Zimmer Biomet (ZBH) struggles with supply delay problem related to some of its products, causing inability to win back lost customers and gain new ones.

                                                Zacks Equity Research

                                                Here's Why You Should Invest in Align Technology (ALGN) Now

                                                by Zacks Equity Research

                                                Align Technology (ALGN) continues to boost investors' confidence on consistent strength in InvisAlign.

                                                  Zacks Equity Research

                                                  PetMed (PETS) Down 7.8% Since Earnings Report: Can It Rebound?

                                                  by Zacks Equity Research

                                                  PetMed (PETS) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.